Seize the future development opportunities of pharmaceutical equipment industry:

     Source: Xiangyu ‍ Pharmaceutical‍

       Coincidentally, Dongfulong has continued to increase its full power in recent years, and its first phase project has been completed and put into operation in 2022, and it is expected that sales will reach 300 million yuan in 2023. In addition, the second phase of the biomedical equipment project with a total investment of 1 billion yuan is currently under construction and is expected to be completed in early 2024.

On March 24 this year, Dongfulong held the groundbreaking ceremony of the Group's biopharmaceutical equipment industry trial production center project. It is reported that its industrial trial production center focuses on cutting-edge technology development, new product development and core product upgrading and information upgrading, which will help improve the company's production capacity in complex preparations such as microspheres, liposomes and drug-loaded fat milk.

From the perspective of the project construction direction of major pharmaceutical machinery enterprises, it is mainly based on the fields of bioengineering. The analysis believes that this is mainly because the market prospects of the domestic biomedical industry are optimistic.

In terms of the market prospects of the domestic biomedical industry, the biomedical industry is one of the strategic emerging industries in China. In recent years, from the national level to the local level, a series of favorable policies have been frequently released to support the high-quality development of the biomedical industry and inject momentum into the high-quality development of the biomedical industry. Data show that the market size of China's biopharmaceutical industry has increased from 183.6 billion yuan in 2016 to 317.2 billion yuan in 2019, with a compound annual growth rate of 20%. It is expected that by 2025, the overall scale of the domestic biopharmaceutical market will exceed 800 billion yuan, showing great potential.

Biopharmaceutical equipment belongs to the upstream of the biopharmaceutical industry, with the rapid development of the biopharmaceutical industry, and the continued growth of investment in the pharmaceutical industry, the demand for biopharmaceutical equipment continues to expand, driving the growth of the entire industry market. However, it is also necessary to see that compared with high-end imported equipment, the overall technology of domestic biopharmaceutical equipment is still relatively weak, some parts and core technologies rely on people, domestic products are mainly for the low-end market, and there is still a lack of competitive domestic enterprises and high-end products in the domestic market. Therefore, this also means that the high-end market replacement space of domestic biopharmaceutical equipment is huge. With the major domestic pharmaceutical machine companies have made efforts in the field of biomedicine, and research and development investment continues to increase, it is expected that the pace of domestic substitution will accelerate in the future.

More please enter：http://www.shanghaixiangyu.com